Milrinone
Milrinone is a medicine given into a vein. A US label for milrinone lactate injection lists it for short-term treatment of patients with acute decompensated heart failure. The label describes it as a positive inotrope, a medicine that strengthens the heartbeat, and a vasodilator, which widens blood vessels. The label says patients receiving it "should be observed closely with appropriate electrocardiographic equipment" and that treatment for "potential cardiac events, which may include life threatening ventricular arrhythmias, must be available." It also says "There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours."
Also called Milrinone lactate
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 52769; UNII 9K8XR81MO8 is the UNII of the salt, milrinone lactate, that the label gives, so it is a broad match; MeSH descriptor D020105 (Milrinone). US drug-label class: Phosphodiesterase 3 Inhibitor (established pharmacologic class, RxClass). The MeSH scope note says it inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. The label read is the Hikma Pharmaceuticals USA label for milrinone lactate (vial and premixed dextrose forms), application ANDA077966, effective 2025-05-08 in openFDA; openFDA lists many other milrinone labels, which were not read. This page records the label indication and the class only: no trial result and no dose is given. The parent class page (inotropes and vasopressors) is not written yet, so the page has no parent link.
Trials at a glance
The figures count the 2 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 2
- Phase 3 or 4
- 2
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Completed | All statuses |
|---|---|---|---|
| Phase 4 | 1 | 1 | 2 |
| All phases | 1 | 1 | 2 |
Conditions these trials study
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- The MeSH scope note says milrinone inhibits cAMP phosphodiesterase type 3 activity in heart muscle and in the smooth muscle of blood vessels. The label calls it a positive inotrope and vasodilator.
Classification codes
-
9K8XR81MO8Milrinone lactate
Claims and evidence
Context Patients for whom the US milrinone lactate injection label lists short-term intravenous treatment: acute decompensated heart failure
- Recipient
- Recipient not specified
- Population
- Patients with acute decompensated heart failure, as the indications section describes them; the sentence does not name an age group.
- Care setting
- Intravenous medicine used with close observation and electrocardiographic equipment, as the indications section describes
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the indication sentence
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with acute decompensated heart failure
- Excluded
- None stated
The US label of milrinone lactate injection (Hikma Pharmaceuticals, abbreviated application ANDA077966; version dated 8 May 2025 in openFDA) lists the medicine for short-term intravenous treatment of patients with acute decompensated heart failure. The same section says that patients receiving milrinone "should be observed closely with appropriate electrocardiographic equipment" and that the facility for immediate treatment of "potential cardiac events, which may include life threatening ventricular arrhythmias, must be available." It also says "There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours." The label describes the medicine as a positive inotrope and vasodilator with little chronotropic activity.
Applies to Recipient not specified Patients for whom the US milrinone lactate injection label lists short-term intravenous treatment: acute decompensated heart failure
- Certainty method
- Not assessed
- Limitations
- This claim records what one generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications section and the first sentence of the pharmacology section were read; contraindications, warnings, doses, interactions and adverse reactions were not recorded. The label covers both the vial and the premixed dextrose product. openFDA says its data are unvalidated and not to be relied on for decisions about medical care. openFDA lists many other milrinone labels from other makers, which were not read.
- Last checked
- 2026-11-08
- Next evidence check due
- Not scheduled
Sources and citations (8)
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].effective_time
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].openfda.brand_name[0]
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].indications_and_usage[0], 1 sentence 1
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].indications_and_usage[0], 1 sentence 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].indications_and_usage[0], 1 sentence 3
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].indications_and_usage[0], 1 sentence 5
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].clinical_pharmacology[0], 1
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
While breastfeeding 1
The US label of milrinone lactate injection (Hikma Pharmaceuticals, abbreviated application ANDA077966; version dated 8 May 2025 in openFDA) lists the medicine for short-term intravenous treatment of patients with acute decompensated heart failure. The same section says that patients receiving milrinone "should be observed closely with appropriate electrocardiographic equipment" and that the facility for immediate treatment of "potential cardiac events, which may include life threatening ventricular arrhythmias, must be available." It also says "There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours." The label describes the medicine as a positive inotrope and vasodilator with little chronotropic activity.
Applies to Recipient not specified Patients for whom the US milrinone lactate injection label lists short-term intravenous treatment: acute decompensated heart failure
Population, setting and follow-up
- Patients with acute decompensated heart failure, as the indications section describes them; the sentence does not name an age group.
- Intravenous medicine used with close observation and electrocardiographic equipment, as the indications section describes
- United States (label of the US Food and Drug Administration)
- Not stated in the indication sentence
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records what one generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications section and the first sentence of the pharmacology section were read; contraindications, warnings, doses, interactions and adverse reactions were not recorded. The label covers both the vial and the premixed dextrose product. openFDA says its data are unvalidated and not to be relied on for decisions about medical care. openFDA lists many other milrinone labels from other makers, which were not read.
- Last checked
- 2026-11-08
- Next evidence check due
- Not scheduled
Sources and citations (8)
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].effective_time
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].openfda.brand_name[0]
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].indications_and_usage[0], 1 sentence 1
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].indications_and_usage[0], 1 sentence 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].indications_and_usage[0], 1 sentence 3
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].indications_and_usage[0], 1 sentence 5
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)
- Locator
- results[0].clinical_pharmacology[0], 1
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2025-05-08
- Source state
- Current
- Version fingerprint
852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
PRIMACOR
No label from the application holder was found in the openFDA label dataset for application NDA019436. This page does not show another labeler's label in its place.
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA020343. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact The US label lists short-term intravenous treatment of acute decompensated heart failure: Heart failure
Applies to Recipient not specified Patients for whom the US milrinone lactate injection label lists short-term intravenous treatment: acute decompensated heart failure
The US label of milrinone lactate injection (Hikma Pharmaceuticals, abbreviated application ANDA077966; version dated 8 May 2025 in openFDA) lists the medicine for short-term intravenous treatment of patients with acute decompensated heart failure. The same section says that patients receiving milrinone "should be observed closely with appropriate electrocardiographic equipment" and that the facility for immediate treatment of "potential cardiac events, which may include life threatening ventricular arrhythmias, must be available." It also says "There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours." The label describes the medicine as a positive inotrope and vasodilator with little chronotropic activity.Limitations. This claim records what one generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications section and the first sentence of the pharmacology section were read; contraindications, warnings, doses, interactions and adverse reactions were not recorded. The label covers both the vial and the premixed dextrose product. openFDA says its data are unvalidated and not to be relied on for decisions about medical care. openFDA lists many other milrinone labels from other makers, which were not read.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 2
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Record details
- Record id
cardio:milrinone- Content hash
88d6d1b68f556082ab245dfcc223ff5470d15f20218759cf42343f51c7078763